论文部分内容阅读
通过对３０名慢性气道阻塞性疾病患者进行定量吸入器（ＭＤＩ）与定量吸入器连接贮雾助吸器（ｓｐａｃｅｒ）吸入β２受体兴奋剂疗效的对照观察，证明ＭＤＩ连接ｓｐａｃｅｒ吸入β２兴奋剂，可明显减少药雾在咽部的沉积，使肺内沉积率提高５５．８％（Ρ＜０．００１），从而显著提高ＦＥＶ１．０（Ｐ＜０．０５）、ＰＥＦ（Ｐ＜０．０５）、Ｖ５０（Ｐ＜０．０５）及Ｖ２５（Ｐ＜０．０１）４项指标，减少用药量及心血管副作用。且不需特殊训练，不需吸气与手术动作配合及较长时间屏气。尤适用于老人、肺功能差及气急明显者。
By comparing the efficacy of MDI inhalation with inhalation of β2 receptor agonists by a metered-dose inhaler and spacer spacer in 30 patients with chronic airway obstructive disease, it was demonstrated that MDI connection spacer inhaled β2 agonist, (P <0.05), PEF (P <0.05), PEF (P <0.05), and the deposition rate in the lung increased 55.8% (P <0.001) ), V50 (P <0.05) and V25 (P <0.01), and the dosage and cardiovascular side effects were decreased. And without special training, without breathing and surgical action with a longer time breath holding. Especially suitable for the elderly, poor lung function and those who have shortness of breath obviously.